Innovation
Entrepreneurship and innovation enable Weill Cornell Medicine to bring discoveries to patients faster.
Weill Cornell Medicine investigators enjoy robust programs dedicated to nurturing, protecting and commercializing their discoveries. By translating groundbreaking research into revolutionary care through commercial partnerships, lifechanging diagnostics, treatments and healthcare solutions can reach patients faster than ever before. Weill Cornell Medicine Enterprise Innovation fosters a culture of innovation and entrepreneurship to build the next generation of leaders in life sciences industries and new ventures.
News
From Academic Scientist to Biotech Executive
Dr. Vishwas Seshadri, CEO of Abeona Therapeutics, conversed with BioVenture eLab Director Loren Busby on R&D, manufacturing, leadership, regulatory affairs and market access.
Innovative Discovery Could Revolutionize Kidney Transplant Rejection Diagnostics
Dr. Manikkam Suthanthiran discovered that biological evidence of kidney transplant rejection can be detected in urine, which led to the development of a urine gene expression biomarker test.
Exploring Human Voice as a Biomarker
Weill Cornell clinicians and researchers hope to harness voice data to detect signs of diseases and train AI algorithm to improve the accuracy of diagnoses and predict disease progression.
Wound Healing Innovation Obtains FDA 510(K) Clearance to Help Improve Patient Outcomes
Fesarius Therapeutics, a startup founded by Dr. Jason Spector, obtained FDA clearance to market and distribute its innovative collagen-based dermal matrices for improved wound healing.
Views on Innovation
Dr. Barbara Hempstead, Dean, Weill Cornell Graduate School of Medical Sciences
Our accomplished physicians and scientists have a legacy of catalyzing research discoveries into new modalities and therapies that help transform human health.
Dr. Lisa Placanica, Senior Managing Director, Center for Technology Licensing at Weill Cornell Medicine
We partner with faculty and commercial entities to shape translational research into intellectual property that leads to health care products, services, tools.
Dr. William Polvino, CEO of Bridge Medicines
Tri-Institutional Therapeutics Discovery Institute and Bridge Medicines put the skill of a pharmaceutical company on the campuses of three great institutions.
Dr. Francis Barany, Professor of Microbiology and Immunology
The professionals at Enterprise Innovation possess strong first-hand knowledge of what it takes to start a company.
Become Engaged